Medical Bioremediation of Age-related Diseases
Overview
Microbiology
Affiliations
Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods.
7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19.
Ghzaiel I, Sassi K, Zarrouk A, Nury T, Ksila M, Leoni V J Steroid Biochem Mol Biol. 2021; 212:105939.
PMID: 34118414 PMC: 8188774. DOI: 10.1016/j.jsbmb.2021.105939.
Cholesterol Degradation and Production of Extracellular Cholesterol Oxidase from W1 and W8.
Wali H, Rehman F, Umar A, Ahmed S Biomed Res Int. 2019; 2019:1359528.
PMID: 31183360 PMC: 6512041. DOI: 10.1155/2019/1359528.
Current therapeutic developments in atrophic age-related macular degeneration.
Hanus J, Zhao F, Wang S Br J Ophthalmol. 2015; 100(1):122-7.
PMID: 26553922 PMC: 4944382. DOI: 10.1136/bjophthalmol-2015-306972.